Adage Capital Partners
BEAM icon

Adage Capital Partners’s Beam Therapeutics BEAM Stock Holding History

Adage Capital Partners’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-175,000
Closed -$4.25M – 921
2025
Q3 		$4.25M Buy
+175,000
New +$3.48M 0.01% 751
2020
Q3 		– Sell
-358,000
Closed -$10M – 760
2020
Q2 		$10M Buy
358,000
+26,000
+8% +$560K 0.03% 523
2020
Q1 		$5.98M Buy
+332,000
New +$7.22M 0.02% 555

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Adage Capital Partners's BEAM Position: Q4 2025 in Review

Adage Capital Partners sold out of Beam Therapeutics (BEAM) in Q4 2025, closing a stake of 175,000 shares — an estimated $4.25M sold.

Adage Capital Partners first reported a position in BEAM in Q1 2020 and held it in 3 quarters. The position peaked at $10M in Q2 2020. 246 funds tracked by Wall St. Rank hold BEAM as of Q4 2025.

  • Adage Capital Partners reported no remaining Beam Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Adage Capital Partners sold 175,000 Beam Therapeutics shares in Q4 2025, an estimated $4.25M.
  • Adage Capital Partners first reported a position in Beam Therapeutics in Q1 2020 and held it in 3 quarters.
  • Adage Capital Partners's Beam Therapeutics position peaked at $10M in Q2 2020.
  • 246 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2025.

Based on Adage Capital Partners's 13F filing for Q4 2025, filed 17 Feb 2026.